Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KT
Pasithea Therapeutics Corp. Common Stock
KTTA
Volume
207.18K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KT
KTTA
KT
Pasithea Therapeutics Corp. Common Stock
KTTA
News
·
NOTICE TO DISREGARD -- Thea Foundation
Mkt Cap
$13.7M
Volume
207.18K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
NOTICE TO DISREGARD -- Thea Foundation
THEA, a predictive behavioral AI network focused on risk markets, announced $8 million in financing led by Maven11 Capital. However, the article begins with a retraction notice advising readers to disregard the original news release, creating significant uncertainty about the announcement's validity.
GlobeNewswire Inc. · Jul 2, 2026
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Pasithea Therapeutics raised $60 million through a public offering of 80 million shares at $0.75 per share, led by healthcare investors. The proceeds will support ongoing research and extend the company's cash runway through the first half of 2028.
GlobeNewswire Inc. · Dec 2, 2025
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Pasithea Therapeutics reported positive pharmacokinetic data for its PAS-004 tablet in a Phase 1/1b trial for neurofibromatosis type 1 (NF1) patients, demonstrating linear dose-proportionality and improved tablet formulation characteristics.
GlobeNewswire Inc. · Nov 21, 2025
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight
The neurofibromatosis type 1 market is expected to grow significantly due to advances in treatment, increased diagnoses, and ongoing clinical trials. Unmet needs in adult populations and systemic disease management create opportunities for new entrants and differentiated strategies.
GlobeNewswire Inc. · May 15, 2025
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
Pasithea Therapeutics, a clinical-stage biotechnology company, announced the closing of a $5 million public offering to fund its ongoing research, clinical trials, and corporate initiatives.
GlobeNewswire Inc. · May 7, 2025
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
Pasithea Therapeutics, a clinical-stage biotechnology company, announced that its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 CAGLA NeauxCancer Conference in New Orleans. The presentation will provide an overview of Pasithea's next-generation macrocyclic MEK inhibitor, PAS-004, and the company's progress in clinical development.
GlobeNewswire Inc. · Mar 24, 2025
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Pasithea Therapeutics, a clinical-stage biotechnology company, announced a $5 million private placement of its common stock and warrants. The company plans to use the proceeds for working capital and general corporate purposes.
GlobeNewswire Inc. · Sep 26, 2024
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Pasithea Therapeutics announced the successful completion of long-term chronic toxicity studies for its lead candidate PAS-004, a next-generation macrocyclic MEK inhibitor. The studies in rats and dogs showed a consistent safety profile, supporting the potential of PAS-004 as a best-in-class MEK inhibitor.
GlobeNewswire Inc. · Sep 9, 2024
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
GlobeNewswire Inc. · Jan 2, 2024
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
GlobeNewswire Inc. · Dec 28, 2023
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
KT
KTTA
Pasithea Therapeutics Corp. Common Stock
Buy
Sell
Market
Limit
Soon
KTTA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any KTTA yet.
Related Tickers
Earnings